Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CD69 | Q07108 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916742 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL22606183 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL22596723 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL23705217 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL23705274 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL24223153 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL24943853 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL24916806 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL21415435 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 | |
| SCHEMBL14899261 | 1.00 | ALDH1A1 (0.67) | ALDH1A1THRBMAPK1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263897-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2023-08-24 | — | — | US | disclosed |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263897-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | ASGR1, GYS2, HCCS | ALDH1A1 3111/4885THRB 1246/4885MAPK1 4249/4885 |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | ALDH1A1 4541/4885THRB 2461/4885MAPK1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.